Investor Presentaiton
Our ESG updates and looking ahead
ESG Materiality Assessment Results
Completed a global, double ESG materiality assessment¹ and identified the
8 ESG factors that were rated as most "material" by stakeholders
✓ Results showed strong alignment of internal and external stakeholders'
priorities
TOP 8 Material ESG Factors
1. Pricing & Patient Access
2. Product Innovation
3. Patient Safety and Product Quality
4. Ethics & Conduct
5. Long-Term Value Creation
6. Culture and Inclusion & Diversity
7. Climate Change & Emissions
8. Public Health & Public Policy
Breakdown:
Top ESG
Issues by
Theme
Business
Model &
Innovation,
26%
2022 ESG Report
✓ On August 23, 2023, published BMS' 2022 ESG
Report, 2 providing increased transparency and
disclosures
2022
Environmental,
Social and
Governance
Report
Social
Capital,
36%
Bristol Myers Squibb
Leadership &
Governance,
16%
Human
Capital,
11%
Environment,
11%
A
Table of Contents
3
& Accesso
Health Equity
Innovation
Healthcare
27
Our People
35
Ethics, Integrity,
Inclusion &
Diversity
46
Looking Ahead
84
Environmental
Responsibilty
56
Appendix
86
Quality &
Governance
70
Evolved ESG Strategy based on double
materiality assessment will be shared
in 2024
Looking Ahead
Task Force on Climate-Related Financial
Disclosures (TCFD) report will be
published later this year
2022 Highlights Include:
✓ 58% clinical trial sites in diverse metro areas
✓ $1B global spend on diverse-owned businesses
✓ 8.2% reduction in greenhouse gas emissions across
Scopes 1, 2, & 3 compared to 2021
Science-based emissions reduction targets
anticipated to be validated by the Science
Based Targets Initiative (SBTi) by 2024
$150 million to address
health disparities will be
provided by end of 2025
ll, Bristol Myers Squibb™ | Q3 2023 Results
1 BMS ESG Materiality Assessment
2 BMS 2022 ESG Report
Not for Product Promotional Use
28View entire presentation